This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moghazeh, S. L.
Right arrow Articles by Kreiswirth, B. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moghazeh, S. L.
Right arrow Articles by Kreiswirth, B. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Nov 1996, 2655-2657, Vol 40, No. 11
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

SL Moghazeh, X Pan, T Arain, CK Stover, JM Musser and BN Kreiswirth
Tuberculosis Center, Public Health Research Institute, New York, New York 10016, USA.

A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta- subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM- 1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure- function relationships.


This article has been cited by other articles:

  • Van Deun, A., Barrera, L., Bastian, I., Fattorini, L., Hoffmann, H., Kam, K. M., Rigouts, L., Rusch-Gerdes, S., Wright, A. (2009). Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results. J. Clin. Microbiol. 47: 3501-3506 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K. (2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother. 50: 3658-3664 [Abstract] [Full Text]  
  • Cavusoglu, C., Turhan, A., Akinci, P., Soyler, I. (2006). Evaluation of the Genotype MTBDR Assay for Rapid Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Isolates.. J. Clin. Microbiol. 44: 2338-2342 [Abstract] [Full Text]  
  • Murphy, C. K., Mullin, S., Osburne, M. S., van Duzer, J., Siedlecki, J., Yu, X., Kerstein, K., Cynamon, M., Rothstein, D. M. (2006). In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 827-834 [Abstract] [Full Text]  
  • Kocagoz, T., Saribas, Z., Alp, A. (2005). Rapid Determination of Rifampin Resistance in Clinical Isolates of Mycobacterium tuberculosis by Real-Time PCR. J. Clin. Microbiol. 43: 6015-6019 [Abstract] [Full Text]  
  • McCammon, M. T., Gillette, J. S., Thomas, D. P., Ramaswamy, S. V., Graviss, E. A., Kreiswirth, B. N., Vijg, J., Quitugua, T. N. (2005). Detection of rpoB Mutations Associated with Rifampin Resistance in Mycobacterium tuberculosis Using Denaturing Gradient Gel Electrophoresis. Antimicrob. Agents Chemother. 49: 2200-2209 [Abstract] [Full Text]  
  • Suchland, R. J., Bourillon, A., Denamur, E., Stamm, W. E., Rothstein, D. M. (2005). Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil. Antimicrob. Agents Chemother. 49: 1120-1126 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Van Der Zanden, A. G. M., Te Koppele-Vije, E. M., Vijaya Bhanu, N., Van Soolingen, D., Schouls, L. M. (2003). Use of DNA Extracts from Ziehl-Neelsen-Stained Slides for Molecular Detection of Rifampin Resistance and Spoligotyping of Mycobacterium tuberculosis. J. Clin. Microbiol. 41: 1101-1108 [Abstract] [Full Text]  
  • (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662 [Full Text]  
  • Saribas, Z., Kocagoz, T., Alp, A., Gunalp, A. (2003). Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates by Heteroduplex Analysis and Determination of Rifamycin Cross-Resistance in Rifampin-Resistant Isolates. J. Clin. Microbiol. 41: 816-818 [Abstract] [Full Text]  
  • Qian, L., Abe, C., Lin, T.-P., Yu, M.-C., Cho, S.-N., Wang, S., Douglas, J. T. (2002). rpoB Genotypes of Mycobacterium tuberculosis Beijing Family Isolates from East Asian Countries. J. Clin. Microbiol. 40: 1091-1094 [Abstract] [Full Text]  
  • Lenaerts, A. M., Chase, S. E., Cynamon, M. H. (2000). Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model. Antimicrob. Agents Chemother. 44: 3167-3168 [Abstract] [Full Text]  
  • Bemer-Melchior, P., Bryskier, A., Drugeon, H. B. (2000). Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46: 571-576 [Abstract] [Full Text]  
  • Piddock, L. J. V., Ricci, V. (2000). Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis. J Antimicrob Chemother 45: 681-684 [Abstract] [Full Text]  
  • Lenaerts, A. M. J. A., Chase, S. E., Chmielewski, A. J., Cynamon, M. H. (1999). Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice. Antimicrob. Agents Chemother. 43: 2356-2360 [Abstract] [Full Text]  
  • Portugal, I., Maia, S., Moniz-Pereira, J. (1999). Discrimination of Multidrug-Resistant Mycobacterium tuberculosis IS6110 Fingerprint Subclusters by rpoB Gene Mutation Analysis. J. Clin. Microbiol. 37: 3022-3024 [Abstract] [Full Text]  
  • Pozzi, G., Meloni, M., Iona, E., Orrù, G., Thoresen, O. F., Ricci, M. L., Oggioni, M. R., Fattorini, L., Orefici, G. (1999). rpoB Mutations in Multidrug-Resistant Strains of Mycobacterium tuberculosis Isolated in Italy. J. Clin. Microbiol. 37: 1197-1199 [Abstract] [Full Text]  
  • Telenti, A (1998). Genetics and pulmonary medicine bullet  5: Genetics of drug resistant tuberculosis. Thorax 53: 793-797 [Full Text]  
  • Williams, D. L., Spring, L., Collins, L., Miller, L. P., Heifets, L. B., Gangadharam, P. R. J., Gillis, T. P. (1998). Contribution of rpoB Mutations to Development of Rifamycin Cross-Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42: 1853-1857 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»